This bibliometric analysis is conducted to reveal (1) the most influential clinical studies, the top contributing (2) journals, (3) countries, (4) institutions, and (4) authors, the most studied (5) cancers, and (6) drugs, and (7) the research hotspots of anti-PD1/PDL1 immunotherapy. Here, CD274 is linked to cancer.